CELH Stock Analysis: Celsius Holdings | NASDAQ
Beverages - Non-Alcoholic | NASDAQ, USA | Market Cap: 7.485m USD | 12M Return: -28.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 265M
Qual. Beats: 0
Rev. Trend: 89.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Celsius Holdings, Inc. (NASDAQ: CELH) is a U.S.-based functional energy drink company that develops, manufactures, markets, sells, and distributes its products across the United States, North America, Europe, Asia Pacific, and other international markets. The company offers a range of products including ready-to-drink energy beverages, hydration powders and sticks, and nutrition and wellness items under the CELSIUS, Alani Nu, and Rockstar brand names, with sub-lines such as CELSIUS ESSENTIALS (formulated with amino acids) and CELSIUS Hydration (zero-sugar electrolyte powders in fruit-forward flavors). The company was founded in 2004, is headquartered in Boca Raton, Florida, and operates a broad omnichannel distribution network spanning direct-to-store delivery, independent distributors, supermarkets, convenience and drug stores, food service providers, mass merchants, fitness centers, club and vitamin specialty stores, and e-commerce platforms.
The company operates within the Consumer Staples sector, specifically the Soft Drinks & Non-alcoholic Beverages sub-industry, a mature and highly competitive category traditionally dominated by large incumbents such as Coca-Cola and PepsiCo. Within this space, Celsius has positioned itself in the faster-growing functional and better-for-you beverage segment, targeting active-lifestyle and fitness-oriented consumers through fitness-center and specialty-channel distribution as well as digital channels.
- Alani Nu acquisition accelerates revenue growth and expands consumer base
- Pepsi distribution partnership drives shelf space expansion nationally
- GLP-1 drug adoption pressures functional beverage category demand
| Net Income: 173.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -5.39 > 1.0 |
| NWC/Revenue: 25.72% < 20% (prev 74.75%; Δ -49.03% < -1%) |
| CFO/TA 0.06 > 3% & CFO 329.8m > Net Income 173.7m |
| Net Debt (1.91b) to EBITDA (298.4m): 6.39 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (259.8m) vs 12m ago 9.53% < -2% |
| Gross Margin: 49.62% > 18% (prev 50.43%; Δ -0.81% > 0.5%) |
| Asset Turnover: 84.61% > 50% (prev 71.48%; Δ 13.13% > 0%) |
| Interest Coverage Ratio: 4.31 > 6 (EBIT TTM 262.4m / Interest Expense TTM 60.8m) |
| A: 0.15 (Total Current Assets 1.81b - Total Current Liabilities 1.05b) / Total Assets 5.16b |
| B: 0.05 (Retained Earnings 272.0m / Total Assets 5.16b) |
| C: 0.07 (EBIT TTM 262.4m / Avg Total Assets 3.51b) |
| D: 0.32 (Book Value of Equity 1.25b / Total Liabilities 3.91b) |
| Altman-Z'' = 1.98 = BBB |
| DSRI: 1.45 (Receivables 832.4m/256.4m, Revenue 2.97b/1.33b) |
| GMI: 1.02 (GM 50.43% / 49.62%) |
| AQI: 3.18 (AQ_t 0.63 / AQ_t-1 0.20) |
| SGI: 2.23 (Revenue 2.97b / 1.33b) |
| TATA: -0.03 (NI 173.7m - CFO 329.8m) / TA 5.16b) |
| Beneish M = -0.47 (Cap -4..+1) = D |
As of July 04, 2026, the stock is trading at USD 33.16 with a total of 9,342,800 shares traded. Over the past week, the price has changed by +17.51%, over one month by +10.50%, over three months by -8.22% and over the past year by -28.78%.
Current recommended Stop Loss: 31.10 (which is 6.2% or 1.2 ATR below the current price).
Celsius Holdings has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CELH.
- StrongBuy: 8
- Buy: 6
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 58.5 | 76.4% |
P/E Trailing = 68.093
P/E Forward = 19.2308
P/S = 2.5214
P/B = 6.0887
P/EG = 0.3031
Revenue TTM = 2.97b USD
EBIT TTM = 262.4m USD
EBITDA TTM = 298.4m USD
Long Term Debt = 668.9m USD (from longTermDebt, last quarter)
Short Term Debt = 7.00m USD (from shortTermDebt, last quarter)
Debt = 2.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 19.7m
Net Debt = 1.91b USD (calculated: Debt 2.46b - CCE 549.2m)
Enterprise Value = 9.39b USD (7.49b + Debt 2.46b - CCE 549.2m)
Interest Coverage Ratio = 4.31 (Ebit TTM 262.4m / Interest Expense TTM 60.8m)
EV/FCF = 32.08x (Enterprise Value 9.39b / FCF TTM 292.8m)
FCF Yield = 3.12% (FCF TTM 292.8m / Enterprise Value 9.39b)
FCF Margin = 9.86% (FCF TTM 292.8m / Revenue TTM 2.97b)
Net Margin = 5.85% (Net Income TTM 173.7m / Revenue TTM 2.97b)
Gross Margin = 49.62% ((Revenue TTM 2.97b - Cost of Revenue TTM 1.50b) / Revenue TTM)
Gross Margin QoQ = 48.31% (prev 47.37%)
Tobins Q-Ratio = 1.82 (Enterprise Value 9.39b / Total Assets 5.16b)
Interest Expense / Debt = 2.48% (Interest Expense 60.8m / Debt 2.46b)
Taxrate = 13.84% (27.9m / 201.6m)
NOPAT = 226.1m (EBIT 262.4m * (1 - 13.84%))
Current Ratio = 1.73 (Total Current Assets 1.81b / Total Current Liabilities 1.05b)
Debt / Equity = 1.96 (Debt 2.46b / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 6.39 (Net Debt 1.91b / EBITDA 298.4m)
Debt / FCF = 6.51 (Net Debt 1.91b / FCF TTM 292.8m)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.95% (Net Income 173.7m / Total Assets 5.16b)
RoE = 7.51% (Net Income TTM 173.7m / Total Stockholder Equity 2.31b)
RoCE = 8.80% (EBIT 262.4m / Capital Employed (Equity 2.31b + L.T.Debt 668.9m))
RoIC = 5.70% (NOPAT 226.1m / Invested Capital 3.96b)
WACC = 8.63% (E(7.49b)/V(9.94b) * Re(10.76%) + D(2.46b)/V(9.94b) * Rd(2.48%) * (1-Tc(0.14)))
Discount Rate = 10.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.26 | Cagr: 5.19%
[DCF] Terminal Value 77.07% ; FCFF base≈258.0m ; Y1≈295.7m ; Y5≈435.2m
[DCF] Fair Price = 16.97 (EV 6.24b - Net Debt 1.91b = Equity 4.34b / Shares 255.6m; r=8.63% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 89.91 | Revenue CAGR: 38.68% | SUE: 0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=-0.56% | Revisions=-63% | Analysts=17
EPS next Quarter (2026-09-30): EPS=0.44 | Chg30d=+0.55% | Revisions=-75% | Analysts=17
EPS current Year (2026-12-31): EPS=1.63 | Chg30d=+0.38% | Revisions=+11% | GrowthEPS=+21.7% | GrowthRev=+32.4%
EPS next Year (2027-12-31): EPS=2.02 | Chg30d=-0.61% | Revisions=-5% | GrowthEPS=+23.8% | GrowthRev=+9.6%
[Analyst] Revisions Ratio: -38% (up=20, down=46)